The second one, cited earlier, is a phase I clinical trial (NCT03932565) using fourth-generation CAR-T cells coproducing IL-7 and CCL19/IL-2 in patients with Nectin4-positive advanced malignant solid tumors such as NSCLC, breast, bladder, pancreatic and ovarian cancer. The gene discussed is CCL19; the disease is ovarian carcinoma.